The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Regulatory News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 310.00
Bid: 307.00
Ask: 312.00
Change: 0.00 (0.00%)
Spread: 5.00 (1.629%)
Open: 311.00
High: 314.00
Low: 303.00
Prev. Close: 310.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

7 Jul 2020 08:00

RNS Number : 2351S
Hutchison China Meditech Limited
07 July 2020
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft

Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

 

Hutchison China MediTech Limited

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

X

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

X

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

General Atlantic Singapore HCM Pte. Ltd.

City and country of registered office (if applicable)

Singapore

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

06/07/2020

6. Date on which issuer notified (DD/MM/YYYY):

06/07/2020

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial in- struments

(total of 8.B 1 + 8.B 2)

 

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which

threshold was crossed or reached

 

2.81%

 

2.35%

 

5.16%

 

710,574,765

Position of previous notification (if applicable)

 

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or

reachedviii

A: Voting rights attached to shares

Class/type of shares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Ordinary Shares KYG4672N1198

20,000,000

2.81%

SUBTOTAL 8. A

20,000,000

2.81%

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

 

Type of financial instrument

 

Expiration datex

 

Exercise/ Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

 

% of voting rights

SUBTOTAL 8. B 1

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expiration datex

Exercise/ Conversion Period xi

Physical or cash settlementxii

Number of voting rights

 

% of voting rights

Warrants over

Ordinary Shares

January 3,

2022

At any time after July 2,

2020

Physical

16,666,670

2.35%

SUBTOTAL 8.B.2

16,666,670

2.35%

 

 

9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or the

financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

 

X

 

 

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial in- struments if it equals or is higher than the

notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

GAP (Bermuda) Limited

5.16%

General Atlantic LLC

5.16%

General Atlantic GenPar (Bermuda), L.P.

 

5.16%

General Atlantic (Lux) S.à r.l.

5.16%

General Atlantic GenPar (Lux) SCSp, L.P.

 

5.16%

General Atlantic Part- ners (Bermuda) IV, L.P.

 

5.16%

General Atlantic Part- ners (Bermuda) EU, L.P.

 

5.16%

General Atlantic Part- ners (Lux) SCSp, L.P.

 

5.16%

GAP Coinvestments III, LLC

 

5.16%

GAP Coinvestments IV, LLC

 

5.16%

GAP Coinvestments V, LLC

 

5.16%

GAP Coinvestments CDA, L.P.

 

5.16%

General Atlantic Singa- pore Interholdco Ltd.

 

5.16%

 

 

General Atlantic Singa- pore Fund Pte. Ltd.

 

5.16%

General Atlantic Singa- pore HCM Pte. Ltd.

5.16%

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

 

 

 

11. Additional informationxvi

The warrants in Box B 2 have not been exercised, in part or whole, as of the below "Date of completion." Accordingly, the "Total number of voting rights of issuer" in Box 7 do not account for any issuance of the new voting shares, in part or whole, from the exercise of the warrants.

Once the warrants are exercised in full, assuming no other changes in the interests or the voting shares in the meantime, the "Total number of voting rights of issuer" in Box 7 will become 727,241,435. On that

basis, the ownership ordinary shares would represent 2.75%, the ownership of warrants would represent 2.29%, and the combined ownership of the ordinary shares and warrants would represent 5.04%.

 

 

Place of completion

Hong Kong, China

Date of completion

July 6, 2020

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
HOLUBSNRRKUBRRR
Date   Source Headline
6th Feb 20207:20 amRNSIssue of Equity
4th Feb 20204:40 pmRNSSecond Price Monitoring Extn
4th Feb 20204:35 pmRNSPrice Monitoring Extension
31st Jan 20207:00 amRNSNotice of Results
29th Jan 20207:25 amRNSHolding(s) in Company
23rd Jan 20207:35 amRNSPricing of US$110 Million Public Offering of ADSs
22nd Jan 20207:00 amRNSChi-Med Announces Proposed Offering of ADSs
20th Jan 202010:40 amRNSPositive SANET-p Phase III Clinical Trial Results
13th Jan 20207:00 amRNSChi-Med Starts Surufatinib+PD-1 Ph2 Combo Trial
6th Jan 20207:04 amRNSChi-Med to Present at JP Morgan Conference
31st Dec 20197:00 amRNSBlock Listing Six Monthly Return
31st Dec 20197:00 amRNSTotal Voting Rights
20th Dec 20197:00 amRNSSurufatinib Granted Priority Review in China
12th Dec 20198:57 amRNSGrant of share options
29th Nov 20198:56 amRNSTotal Voting Rights
28th Nov 20197:00 amRNSElunate® Included in China NRDL
25th Nov 20197:47 amRNSChi-Med Highlights Presentations at 2019 ESMO Asia
25th Nov 20197:00 amRNSSurufatinib granted FDA orphan drug designation
11th Nov 20197:00 amRNSSurufatinib China NDA acceptance
17th Oct 20197:26 amRNSChi-Med Ph II gastric cancer data for Savolitinib
10th Oct 201910:22 amRNSGrant of share options under share option scheme
10th Oct 20199:00 amRNSInnovent and Chi-Med Expand Global Collaboration
4th Oct 20197:11 amRNSChi-Med Phase I/Ib Trial of HMPL-523 in Lymphoma
3rd Oct 20198:26 amRNSHolding(s) in Company
30th Sep 20191:49 pmRNSHolding(s) in Company
30th Sep 201912:11 pmRNSHolding(s) in Company
30th Sep 20197:00 amRNSChi-Med Surufatinib Phase III data at ESMO
30th Sep 20197:00 amRNSTotal Voting Rights
25th Sep 20197:00 amRNSChi-Med Presents SANET-ep Phase III data at ESMO
18th Sep 20197:00 amRNSChi-Med Highlights Presentations at 2019 CSCO
3rd Sep 20197:19 amRNSChi-Med to present at MS conference
3rd Sep 20197:00 amRNSChi-Med initiates Phase I trial
30th Aug 20197:00 amRNSTotal Voting Rights
23rd Aug 20197:00 amRNSStart of Clinical Trial in China
20th Aug 20197:48 amRNSHolding(s) in Company
30th Jul 201910:48 amRNSTR-1: Form for notification of major holdings
30th Jul 20197:00 amRNS2019 Interim Results and Clinical Programs Update
10th Jul 20194:35 pmRNSPrice Monitoring Extension
3rd Jul 20197:00 amRNSChi-Med to Announce 2019 Half-Year Results
3rd Jul 20197:00 amRNSTR-1: Form for notification of major holdings
28th Jun 201911:10 amRNSBlocklisting Six Monthly Return
28th Jun 201910:07 amRNSPricing of U.S. Public Secondary Offering of ADSs
28th Jun 20197:00 amRNSSecondary Offering of American Depositary Shares
21st Jun 20194:40 pmRNSSecond Price Monitoring Extn
21st Jun 20194:35 pmRNSPrice Monitoring Extension
19th Jun 20194:35 pmRNSPrice Monitoring Extension
14th Jun 20199:00 amRNSSurufatinib Phase III Study Meets Primary Endpoint
12th Jun 20199:18 amRNSBlock Admission Applications & Total Voting Rights
10th Jun 201912:07 pmRNSSecond Price Monitoring Extn
10th Jun 201912:02 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.